Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-trastuzumab PET/CT as predictive biomarker for T-DM1 sequencing in advanced HER2-positive breast cancer
2024-516253-49-00Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine, trastuzumab and 89Zr-trastuzumab in breast cancer, sponsored by Institut Jules Bordet. Primary endpoints: Characterization of genomic alterations and HER2 expression and Time to treatment failure (TTF). Planned start Feb 2025; status: withdrawn.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516253-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516253-49-00.